Eye Allergy Therapeutics Market - By Drug Class, By Allergy Type, By Dosage Form, By Distribution Channel - Global Forecast 2025 - 2034

Eye Allergy Therapeutics Market Size

The global eye allergy therapeutics market was valued at USD 3.6 billion in 2024. The market is expected to grow from USD 3.8 billion in 2025 to USD 6.2 billion in 2034, at a CAGR of 5.5% during the forecast period. Allergic conjunctivitis is common all over the world due to increased environmental pollution, global warming, and exposure to allergens from substances such as pollen, dust mites, and pets.
 

For example, according to the World Health Organization (WHO), 6.7 million individuals die from air pollution yearly, while 4.2 million die from outdoor air pollution, and there is increased evidence of allergic diseases among eyes in urban towns. This growing incidence of allergic disorders reflects a consistent need for eye allergy treatment in the coming few years.
 

In addition, increased awareness of eye allergies and advanced diagnostic processes enable the identification and treatment of seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) at an earlier stage. For example, the National Institutes of Health (NIH) estimates that 20% of the total world population is affected by an allergy and among them 40–60% have symptoms related to the eyes. This is where the growing demand for expert eye allergy treatments comes among different patient groups.
 

Additionally, investments made by pharmaceutical organizations in research and development aim towards developing novel eye allergy therapeutics that are more effective, with fewer side effects and provide longer relief. The U.S. Food and Drug Administration has approved a multiple new products as treatments for eye allergies over the past few years, both as prescription and over-the-counter forms. For example, in February 2020, the U.S. Food and Drug Administration (FDA) approved Pataday eye allergy drops, which were manufactured and formulated by Alcon, for OTC sale in the U.S., signaling ongoing progress in therapy for patients with eye allergies.
 

Eye Allergy Therapeutics Market Trends

• Increasing number of patients and physicians prefer dual-purpose eye drops that contain mast cell stabilizers and antihistamines. The medications, for example, Olopatadine and Ketotifen eye drops, reduce the use of multiple medications and make treatment compliance more convenient.
   
• Additionally, the demand for combination treatments fuels product sales and development within the market, which is indicative of a shift towards better treatment.
   
• Moreover, e-commerce and online shopping websites are also emerging as the primary means of obtaining eye allergy medication, particularly due to the COVID-19 pandemic. Individuals increasingly prefer home delivery, automated refills, and online offers.
   
• According to the Pharmaceutical Journal, the volume of medicine prescribed by online pharmacies grew by 45% in 2020 owing to the COVID-19 pandemic. This shows that more people are moving towards digital healthcare options.
   
• Moreover, pharmaceutical companies are increasing their online presence and digital marketing campaigns to keep pace with growing demand for digital healthcare solutions, making eye allergy treatments more accessible.
   

Eye Allergy Therapeutics Market Analysis

Based on drug class, the market is segmented into antihistamines, mast cell stabilizers, dual-action agents, corticosteroids, decongestants, immunotherapy, and other drug classes. The antihistamines segment is expected to drive business growth and expand at a CAGR of 5.4%, reaching over USD 2.1 billion by 2034.
 

• Antihistamines deliver immediate relief from eye allergy symptoms, including itching, redness, and watering. For instance, according to the Allergy, Asthma & Clinical Immunology Journal, allergic eye disease is widespread, affecting around 40% of the population in North America, and its prevalence is continuing to rise.
   
• The good safety record and fast response of antihistamines have rendered them the first line of choice for clinicians and patients alike, and this has created growth in this sector of the market.
   
• Additionally, the availability of antihistamine eye drops via prescription or over-the-counter channels makes them easily available to individuals.
   
• The regulatory support for existing drugs like ketotifen and olopatadine to be sold as over-the-counter medications made them more convenient and accessible to patients, making them an important part of allergy management.
   
• For example, in September 2020, the U.S. FDA approved Alaway preservative free (ketotifen fumarate) antihistamine eye drops for relieving itchy eyes. This was the first over-the-counter (OTC) preservative-free formulation eye drop.

Based on allergy type, the eye allergy therapeutics market is segmented into seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). The seasonal allergic conjunctivitis (SAC) segment generated revenue of USD 2 billion in 2024.
 

• Seasonal allergic conjunctivitis takes place predominantly in spring and summer, particularly in temperate regions with high concentrations of pollen and environmental allergens and is highly prevalent.
   
• For instance, the National Institutes of Health (NIH) states that AC is the most prevalent type of ocular allergy and comprises about 90% of all cases. Such seasonal occurrence and high volume of cases leads to stable market demand for SAC treatments.
   
• Moreover, external allergens such as pollen, mold spores, and outdoor air pollution have risen in accordance with urbanization and global warming, leading to increased allergy rates among people.
   
• For instance, according to the WHO, by 2050, at least one in two individuals will be affected by an allergy disorder. This is likely to lead to increased rates of SAC incidence and patient demand for ocular allergy treatment, reflecting the increasing burden of allergic eye disease on healthcare systems.
   
• The existence of over-the-counter SAC remedies allows patients to control symptoms without prescriptions. The availability, along with enhanced consumer knowledge via direct-to-consumer marketing, has grown the OTC market segment.
   

Based on dosage form, the eye allergy therapeutics market is segmented into eye drops, injectables, oral tablets/capsules, and gels and ointments. The eye drops segment generated a revenue of USD 2.3 billion in 2024.
 

• Eye allergies are prevalent, particularly wherein there are urban areas and industrial environments, generating significant demand for eye drops. For instance, the American Association for Pediatric Ophthalmology and Strabismus reports that allergic conjunctivitis is a prevalent eye ailment that occurs in over 20% of the population. Such a high incidence emphasizes the continued need for effective eye drop treatments available in the market.
   
• Additionally, eye drops deliver instant symptom relief by localized administration, reducing systemic side effects.
   
• Their effortless application process and non-surgical nature place them as the first choice of treatment for mild to moderate allergic conjunctivitis, strengthening their market position and fueling the segment growth.
   

Based on distribution channel, the eye allergy therapeutics market is segmented into hospital pharmacy, retail pharmacy, and e-commerce. The retail pharmacy segment generated a revenue of USD 2 billion in 2024.
 

• Large retail pharmacy chains like CVS, Walgreens, and Boots are broadening their in-store and online services, providing eye allergy therapeutics through home delivery and digital prescription management.
   
• Additionally, insurance and reimbursement policies across many countries facilitate access to vital eye allergy therapeutics in retail pharmacies at reasonable prices.
   
• Furthermore, the presence of non-prescription treatments, such as cetirizine, alaway, and zaditor in retail pharmacies, enhances the segment growth.

North America: The U.S. eye allergy therapeutics market was valued at USD 1.5 billion in 2024 and is projected to grow substantially in the coming years.
 

• The U.S. has strict regulations on eye allergy treatments. The FDA approval of emerging treatments, including drug-eluting contact lenses, has enhanced the possibility of improved patient outcomes.
   
• For example, in March 2022, the U.S. FDA approved ACUVUE Theravision, a Johnson & Johnson disposable soft contact lens made of etafilcon A, which releases ketotifen. It was created to help manage itchy eyes induced by allergies. This regulatory support and approval of new treatments is anticipated to provide new avenues for future market growth.
   
• Big box stores like Walmart, Target, and Costco carry pharmacies and have many over-the-counter allergy eye drops.
   
• The integration of pharmacies in shopping malls has simplified the access to treatment for eye allergies for customers as they shop. This has increased the products on offer, and this aids the market to expand in the sector.
   

Europe: UK eye allergy therapeutics market is projected to grow remarkably in the coming years.
 

• Allergic conjunctivitis is common in the UK with numerous patients having ocular symptoms such as itching, redness, and watering. For instance, according to Allergy UK, allergic conjunctivitis occurs in about 20% of the UK population and can be seasonal (hay fever) or all year round.
   
• This rate is extremely high, particularly in spring and early summer, which results in an ongoing demand for allergy medications from retail pharmacies to expand the market in the region.
   
• UK community pharmacies are a significant source of health care as first-contact care for eye allergies and minor conditions. Pharmacists can recommend and supply treatments under the NHS Minor Ailments Service without the need for GP consultations, improving accessibility and treatment speed.
   
• Moreover, according to Community Pharmacy England, 89% of the population in the UK is covered by a community pharmacy that can be reached in a 20-minute walk, highlighting how important these outlets are in coping with seasonal allergic conditions and easing pressure on primary care services.
   

Japan holds a commendable position in the Asia Pacific eye allergy therapeutics market.
 

• Japan has extensive seasonal allergic conjunctivitis (SAC) due to cedar (sugi) and cypress (hinoki) pollen. For instance, according to The Japanese Ministry of Health, Labour and Welfare, about 26.5% of the population in Japan is affected by cedar pollen allergy.
   
• The geography and large cedar forests of the country provide long pollen seasons, and thus the need for eye allergy treatments is high during spring seasons. This heavy disease burden has made Japan a leading market for allergic conjunctivitis therapies in Asia.
   
• Moreover, the presence of  major Japanese pharmaceutical companies, including Santen Pharmaceutical, ROHTO Pharmaceutical, and Kowa Company, that manufacture distinctive eye drop products for the local market, is driving market growth in the region.
   
• They offer preservative-free products, cooling effect, and long-lasting products via different channels. These attributes have resulted in customer retention and ongoing demand for products in Japan, pushing the market forward.
   

Saudi Arabia in the Middle East and Africa is expected to witness lucrative growth in the eye allergy therapeutics market.
 

• Saudi Arabia's arid climate, frequent dust storms, and high pollen levels contribute to a high prevalence of allergic conjunctivitis and allergic rhinitis. The exposure to desert dust and airborne irritants increases the demand for antihistamine and lubricating eye drops, particularly during spring and summer.
   
• This environmental burden has led to allergic conjunctivitis becoming one of the most frequently reported ophthalmic conditions in Saudi primary healthcare centers. For instance, according to the National Institutes of Health (NIH), allergic conjunctivitis was estimated to affect approximately 2.1 million adults in Saudi Arabia in 2020.
   
• Additionally, the Vision 2030 strategy in Saudi Arabia emphasizes healthcare reform, focusing on increased access to community pharmacies and primary care services.
   
• The shift toward treating minor conditions, including allergic eye diseases, at pharmacies instead of hospitals has expanded the distribution of therapeutics through retail outlets in the country, driving the market growth in the region.
   

Eye Allergy Therapeutics Market Share

The market is fragmented, featuring multiple pharmaceutical firms having approved products. The top four players in this market include Alcon, Santen Pharmaceutical, Bausch Health, and Johnson & Johnson, which account for approximately 40% of the market share. These players are constantly investing in the development of advanced products to enhance eye allergy treatment.
 

Moreover, strategic partnerships with research institutions and healthcare providers have become critical for integrating modern technologies and expanding distribution, which has enabled the companies to address the surge in demand for treatment options. Owing to regulatory support and streamlined approval processes, which further motivate innovation and facilitate market entry, contribute to increased competition in the market. Emerging players are focusing on the development of new treatments that aim to improve eye allergy management. These innovations continue to promote market progression.
 

Eye Allergy Therapeutics Market Companies

Prominent players operating in the eye allergy therapeutics industry include:

• AbbVie
• Akorn
• Alcon
• Bausch Health
• Hikma Pharmaceuticals
• Johnson & Johnson
• Mylan
• Nicox
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Santen Pharmaceutical
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries

• Alcon competes in the eye allergy therapeutics business with a focused expertise in ophthalmology and a broad portfolio of prescription and over-the-counter (OTC) eye care solutions. With integrated business activities that include R&D, manufacturing, and worldwide distribution, Alcon achieves market presence and brand visibility during allergy seasons.
   
• Bausch Health, via its Bausch + Lomb unitbhas a market presence backed by its broad portfolio of eye care that includes pharmaceuticals, contact lenses, and surgical devices. The company's retail and professional distribution networks are well established, thus ensuring consistent availability of products throughout allergy seasons.
   
• Santen Pharmaceutical is an ophthalmology business with a focus on the treatments for allergic conjunctivitis. Santen has established market-specific products, mainly in Asian markets due to the prevalence of cedar pollen allergy. Santen emphasizes the formulation of preservative-free products and region-specific marketing.
   

Eye Allergy Therapeutics Industry News:

• In February 2025, Grünenthal and Apotex Inc. entered into a strategic licensing agreement granting Apotex exclusive Canadian rights to Qutenza, a topical, non-systemic, non-opioid pain patch for neuropathic pain management. The agreement strengthened Grünenthal’s international reach and expanded Qutenza’s market presence in Canada.
   
• In January 2025, Vertex Pharmaceuticals announced that the U.S. FDA approved JOURNAVX (suzetrigine), an oral, non-opioid NaV1.8 pain signal inhibitor, for treating moderate-to-severe acute pain in adults. The drug demonstrated effectiveness, tolerability, and no evidence of addictive potential across various pain types. This approval strengthened Vertex’s position in the pain management market and expanded its non-opioid treatment portfolio.
   
• In November 2024, Grünenthal announced that its U.S. subsidiary, Averitas Pharma, Inc., completed recruitment for the Phase III AV001 clinical trial evaluating the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system for post-surgical neuropathic pain (PSNP). If successful, the trial could support a U.S. label extension, enhancing Grünenthal’s market presence and expanding QUTENZA’s therapeutic applications.
   

The eye allergy therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Antihistamines
• Mast cell stabilizers
• Dual-action agents
• Corticosteroids
• Decongestants
• Immunotherapy
• Other drug classes

Market, By Allergy Type

• Seasonal allergic conjunctivitis (SAC)
• Perennial allergic conjunctivitis (PAC)
• Vernal keratoconjunctivitis (VKC)
• Atopic keratoconjunctivitis (AKC)
• Giant papillary conjunctivitis (GPC)

Market, By Dosage Form

• Eye drops
• Injectables
• Oral tablets/capsules
• Gels and ointments

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE